We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.

Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

With operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Shanghai/Suzhou, China, we also license our core platform technology to other companies and academic institutions globally.
友情链接:澳门百家樂app  电脑版网投  凤凰娱乐登录  梦之城平台登录  亿万先生手机版  利来w66.com  永乐国际f66.Com